NO326404B1 - Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament - Google Patents

Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament Download PDF

Info

Publication number: NO326404B1
Authority: NO; Norway
Prior art keywords: microemulsion; microemulsion according; surfactant; polar phase; carbon atoms
Prior art date: 1995-09-12

Application number

NO19981021A

Other languages

English (en)

Norwegian (no)

Other versions

NO981021D0 (no

NO981021L (no

Inventor

Christian Von Corswant

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-12

Filing date

1998-03-09

Publication date

2008-11-24

1998-03-09 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

1998-03-09 Publication of NO981021D0 publication Critical patent/NO981021D0/no

1998-03-09 Publication of NO981021L publication Critical patent/NO981021L/no

2008-11-24 Publication of NO326404B1 publication Critical patent/NO326404B1/no

Links

239000004530 micro-emulsion Substances 0.000 title claims abstract description 76
239000003814 drug Substances 0.000 title claims description 12
238000000034 method Methods 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title description 3
239000004094 surface-active agent Substances 0.000 claims abstract description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
239000000203 mixture Substances 0.000 claims abstract description 29
150000001875 compounds Chemical class 0.000 claims abstract description 21
239000003981 vehicle Substances 0.000 claims abstract description 15
239000003607 modifier Substances 0.000 claims abstract description 14
230000002209 hydrophobic effect Effects 0.000 claims abstract description 9
231100000252 nontoxic Toxicity 0.000 claims abstract description 6
230000003000 nontoxic effect Effects 0.000 claims abstract description 6
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 5
239000003795 chemical substances by application Substances 0.000 claims abstract description 5
239000000787 lecithin Substances 0.000 claims abstract description 5
229940067606 lecithin Drugs 0.000 claims abstract description 5
235000010445 lecithin Nutrition 0.000 claims abstract description 5
150000003408 sphingolipids Chemical class 0.000 claims abstract description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
125000004432 carbon atom Chemical group C* 0.000 claims description 18
150000004665 fatty acids Chemical class 0.000 claims description 18
235000014113 dietary fatty acids Nutrition 0.000 claims description 15
239000000194 fatty acid Substances 0.000 claims description 15
229930195729 fatty acid Natural products 0.000 claims description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
239000003921 oil Substances 0.000 claims description 11
-1 hydroxyethyl lactamide Chemical compound 0.000 claims description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
150000005690 diesters Chemical class 0.000 claims description 8
239000011780 sodium chloride Substances 0.000 claims description 8
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
239000002202 Polyethylene glycol Substances 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
239000000600 sorbitol Substances 0.000 claims description 6
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
239000003833 bile salt Substances 0.000 claims description 5
229940093761 bile salts Drugs 0.000 claims description 5
238000007911 parenteral administration Methods 0.000 claims description 5
229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
239000004698 Polyethylene Substances 0.000 claims description 4
150000002016 disaccharides Chemical class 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
150000002772 monosaccharides Chemical class 0.000 claims description 4
229940113115 polyethylene glycol 200 Drugs 0.000 claims description 4
229940068886 polyethylene glycol 300 Drugs 0.000 claims description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
239000004359 castor oil Substances 0.000 claims description 3
235000019438 castor oil Nutrition 0.000 claims description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
238000010438 heat treatment Methods 0.000 claims description 3
229940083466 soybean lecithin Drugs 0.000 claims description 3
150000005691 triesters Chemical class 0.000 claims description 3
RSBHKNDSJJBCMN-UHFFFAOYSA-N 1-(1-hydroxyethyl)pyrrolidin-2-one Chemical compound CC(O)N1CCCC1=O RSBHKNDSJJBCMN-UHFFFAOYSA-N 0.000 claims description 2
229940114069 12-hydroxystearate Drugs 0.000 claims description 2
KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical class CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims description 2
229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
239000003741 agents affecting lipid metabolism Substances 0.000 claims description 2
230000001476 alcoholic effect Effects 0.000 claims description 2
229930013930 alkaloid Natural products 0.000 claims description 2
150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
230000003444 anaesthetic effect Effects 0.000 claims description 2
230000001430 anti-depressive effect Effects 0.000 claims description 2
239000003146 anticoagulant agent Substances 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
230000003078 antioxidant effect Effects 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
239000000480 calcium channel blocker Substances 0.000 claims description 2
239000000824 cytostatic agent Substances 0.000 claims description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
229940093471 ethyl oleate Drugs 0.000 claims description 2
150000002194 fatty esters Chemical class 0.000 claims description 2
229930182478 glucoside Natural products 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
230000001861 immunosuppressant effect Effects 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
239000003176 neuroleptic agent Substances 0.000 claims description 2
230000000701 neuroleptic effect Effects 0.000 claims description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
229940126409 proton pump inhibitor Drugs 0.000 claims description 2
239000000612 proton pump inhibitor Substances 0.000 claims description 2
239000002461 renin inhibitor Substances 0.000 claims description 2
229940086526 renin-inhibitors Drugs 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
238000003756 stirring Methods 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
229940005513 antidepressants Drugs 0.000 claims 1
239000002876 beta blocker Substances 0.000 claims 1
229940097320 beta blocking agent Drugs 0.000 claims 1
229920000573 polyethylene Polymers 0.000 claims 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 14
239000012071 phase Substances 0.000 description 14
230000004872 arterial blood pressure Effects 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
241000700159 Rattus Species 0.000 description 9
238000005191 phase separation Methods 0.000 description 7
238000001802 infusion Methods 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 3
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
239000013543 active substance Substances 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
229960003580 felodipine Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000008139 complexing agent Substances 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
VBCKYDVWOPZOBA-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxymethyl)oxolane Chemical compound C1CCOC1COCC1CCCO1 VBCKYDVWOPZOBA-UHFFFAOYSA-N 0.000 description 1
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
241000219000 Populus Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000000059 bradycardiac effect Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
RXXXUIOZOITBII-UHFFFAOYSA-N indeno[1,2-g]indole Chemical compound C1=C2C=CC=CC2=C2C1=C1N=CC=C1C=C2 RXXXUIOZOITBII-UHFFFAOYSA-N 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
229940074928 isopropyl myristate Drugs 0.000 description 1
229940075495 isopropyl palmitate Drugs 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
210000004705 lumbosacral region Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
229960001620 methohexital sodium Drugs 0.000 description 1
KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000223 polyglycerol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Dispersion Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Colloid Chemistry (AREA)

NO19981021A 1995-09-12 1998-03-09 Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament NO326404B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9503143A SE9503143D0 (sv)	1995-09-12	1995-09-12	New preparation
PCT/SE1996/001097 WO1997009964A1 (en)	1995-09-12	1996-09-04	Microemulsions for use as vehicles for administration of active compounds

Publications (3)

Publication Number	Publication Date
NO981021D0 NO981021D0 (no)	1998-03-09
NO981021L NO981021L (no)	1998-03-09
NO326404B1 true NO326404B1 (no)	2008-11-24

Family

ID=20399446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19981021A NO326404B1 (no)	1995-09-12	1998-03-09	Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament

Country Status (27)

Country	Link
US (1)	US6602511B2 (pt)
EP (1)	EP0850046B1 (pt)
JP (1)	JP4203123B2 (pt)
KR (1)	KR100448953B1 (pt)
CN (1)	CN1160057C (pt)
AT (1)	ATE228822T1 (pt)
AU (1)	AU702366B2 (pt)
BR (1)	BR9610089A (pt)
CA (1)	CA2230730C (pt)
CZ (1)	CZ64398A3 (pt)
DE (1)	DE69625213T2 (pt)
DK (1)	DK0850046T3 (pt)
EE (1)	EE9800070A (pt)
ES (1)	ES2186802T3 (pt)
HU (1)	HUP9901215A3 (pt)
IL (1)	IL123638A (pt)
IS (1)	IS4675A (pt)
MX (1)	MX9801755A (pt)
NO (1)	NO326404B1 (pt)
NZ (1)	NZ318530A (pt)
PL (1)	PL325825A1 (pt)
PT (1)	PT850046E (pt)
RU (1)	RU2164134C2 (pt)
SE (1)	SE9503143D0 (pt)
SK (1)	SK282390B6 (pt)
TR (1)	TR199800437T1 (pt)
WO (1)	WO1997009964A1 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9503143D0 (sv)	1995-09-12	1995-09-12	Astra Ab	New preparation
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6489346B1 (en)	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6458373B1 (en)	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US7030155B2 (en)	1998-06-05	2006-04-18	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
DE69942205D1 (de) *	1998-08-13	2010-05-12	Cima Labs Inc	Microemulsionen als feste dosisformen zur oralen verabreichung
DE19859427A1 (de) *	1998-12-22	2000-06-29	Beiersdorf Ag	Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen
GB9912476D0 (en)	1999-05-28	1999-07-28	Novartis Ag	Organic compounds
FR2795960B1 (fr) *	1999-07-05	2001-10-19	Sanofi Elf	Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions
KR100441167B1 (ko) *	2001-12-27	2004-07-21	씨제이 주식회사	마이크로에멀젼 예비 농축액 조성물
US7380606B2 (en) *	2002-03-01	2008-06-03	Cesi Chemical, A Flotek Company	Composition and process for well cleaning
US20050124705A1 (en) *	2002-03-28	2005-06-09	Beiersdorf Ag	Cosmetic or pharmaceutical, low-viscosity oil-in-water emulsions containing phospholipids
US7811594B2 (en)	2002-03-28	2010-10-12	Beiersdorf Ag	Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
DE10213957A1 (de) *	2002-03-28	2003-10-09	Beiersdorf Ag	Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
DE10213955A1 (de) *	2002-03-28	2003-10-09	Beiersdorf Ag	Kosmetische oder pharmazeutische phospholipidhaltige, niedrigviskose (versprühbare) O/W-Emulsionen
DK1517682T3 (da) *	2002-06-28	2007-02-26	Speedel Pharma Ag	Farmaceutisk formulering indeholdende en ikke-peptidisk renininhibitor og et overfladeaktivt stof
US20040136943A1 (en) *	2002-12-27	2004-07-15	Kao Corporation	Skin cleansing composition
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PE20050596A1 (es) *	2003-12-19	2005-10-18	Novartis Ag	Microemulsion que comprende un inhibidor renina
KR20070005617A (ko)	2004-02-13	2007-01-10	바이오어베일러빌리티, 아이엔씨.	마취용 고농도 프로포폴 마이크로에멀젼 조제물
US7727576B2 (en) *	2004-04-16	2010-06-01	Hewlett-Packard Development Company, L.P.	System and a method for producing layered oral dosage forms
US20050232974A1 (en) *	2004-04-19	2005-10-20	Gore Makarand P	System and a method for pharmaceutical dosage preparation using jettable microemulsions
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060222692A1 (en) *	2005-03-31	2006-10-05	Fairfield Clinical Trials Llc	Method and compositions for transdermal administration of antimicrobial medications
US10137083B2 (en) *	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
US11311477B2 (en) *	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US9918934B2 (en) *	2006-12-12	2018-03-20	Edgar Joel Acosta-Zara	Linker-based lecithin microemulsion delivery vehicles
EP1938801A1 (en) *	2006-12-22	2008-07-02	Biofrontera Bioscience GmbH	Nanoemulsion
US20080199589A1 (en) *	2007-02-20	2008-08-21	Cargill, Incorporated	Lipid Microemulsions
EP1985298A1 (en)	2007-04-24	2008-10-29	Azad Pharma AG	Ophtalmic oil-in-water emulsions containing prostaglandins
US9222013B1 (en)	2008-11-13	2015-12-29	Cesi Chemical, Inc.	Water-in-oil microemulsions for oilfield applications
KR101834577B1 (ko)	2009-08-14	2018-03-05	옵코 헬스, 인크.	뉴로키닌-1 길항제의 정맥내 제형
JP4834775B2 (ja)	2010-03-04	2011-12-14	株式会社資生堂	日焼け止め用組成物
NL2005365C2 (en) *	2010-09-17	2012-03-20	Univ Delft Tech	Carbon nanostructures and networks produced by chemical vapor deposition.
WO2013158567A1 (en)	2012-04-15	2013-10-24	Cesi Chemical, Inc.	Surfactant formulations for foam flooding
US11407930B2 (en)	2012-05-08	2022-08-09	Flotek Chemistry, Llc	Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US9200192B2 (en)	2012-05-08	2015-12-01	Cesi Chemical, Inc.	Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US9801819B2 (en) *	2012-06-28	2017-10-31	Johnson & Johnson Consumer Inc.	Racecadotril compositions
CN104411299B (zh) *	2012-06-28	2017-11-10	麦克内尔-Ppc股份有限公司	消旋卡多曲类脂组合物
US10941106B2 (en)	2013-03-14	2021-03-09	Flotek Chemistry, Llc	Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US9068108B2 (en)	2013-03-14	2015-06-30	Cesi Chemical, Inc.	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US9321955B2 (en)	2013-06-14	2016-04-26	Flotek Chemistry, Llc	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US9884988B2 (en)	2013-03-14	2018-02-06	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US9464223B2 (en)	2013-03-14	2016-10-11	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US9428683B2 (en)	2013-03-14	2016-08-30	Flotek Chemistry, Llc	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US9868893B2 (en)	2013-03-14	2018-01-16	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US10577531B2 (en)	2013-03-14	2020-03-03	Flotek Chemistry, Llc	Polymers and emulsions for use in oil and/or gas wells
US10053619B2 (en)	2013-03-14	2018-08-21	Flotek Chemistry, Llc	Siloxane surfactant additives for oil and gas applications
US10421707B2 (en)	2013-03-14	2019-09-24	Flotek Chemistry, Llc	Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10000693B2 (en)	2013-03-14	2018-06-19	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US11254856B2 (en)	2013-03-14	2022-02-22	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US10287483B2 (en)	2013-03-14	2019-05-14	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
US10590332B2 (en)	2013-03-14	2020-03-17	Flotek Chemistry, Llc	Siloxane surfactant additives for oil and gas applications
US10717919B2 (en)	2013-03-14	2020-07-21	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US11180690B2 (en)	2013-03-14	2021-11-23	Flotek Chemistry, Llc	Diluted microemulsions with low surface tensions
US9890625B2 (en)	2014-02-28	2018-02-13	Eclipse Ior Services, Llc	Systems and methods for the treatment of oil and/or gas wells with an obstruction material
US9890624B2 (en)	2014-02-28	2018-02-13	Eclipse Ior Services, Llc	Systems and methods for the treatment of oil and/or gas wells with a polymeric material
CA2891278C (en)	2014-05-14	2018-11-06	Cesi Chemical, Inc.	Methods and compositions for use in oil and / or gas wells
US9957779B2 (en)	2014-07-28	2018-05-01	Flotek Chemistry, Llc	Methods and compositions related to gelled layers in oil and/or gas wells
JP2017181387A (ja) *	2016-03-31	2017-10-05	株式会社ポーラファルマ	医薬組成物の形成する膜の評価方法
US10934472B2 (en)	2017-08-18	2021-03-02	Flotek Chemistry, Llc	Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
US11053433B2 (en)	2017-12-01	2021-07-06	Flotek Chemistry, Llc	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
CN109401745B (zh) *	2018-11-21	2021-03-12	西南石油大学	一种自适应流度控制体系及其在高温高盐油藏的应用
US11104843B2 (en)	2019-10-10	2021-08-31	Flotek Chemistry, Llc	Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
US11512243B2 (en)	2020-10-23	2022-11-29	Flotek Chemistry, Llc	Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2553666B1 (fr)	1983-10-21	1986-10-31	Correia Gabriel	Dispositif permettant de sentir individuellement odeurs et parfums en liaison avec des images et des sons
DE3406497A1 (de)	1984-02-23	1985-09-05	Mueller Bernhard Willi Werner	Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
IL78929A0 (en)	1985-07-29	1986-09-30	Abbott Lab	Microemulsion compositions for parenteral administration
FR2628632B1 (fr) *	1988-03-18	1992-04-03	Gattefosse Ets Sa	Microemulsions a usage cosmetique ou pharmaceutique
AU614465B2 (en) *	1989-04-05	1991-08-29	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Medicinal emulsions
US5364632A (en) *	1989-04-05	1994-11-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Medicinal emulsions
DE69229779T2 (de)	1991-04-19	1999-12-23	Lds Technologies, Inc.	Konvertierbare mikroemulsionsverbindungen
DK0597007T3 (da)	1991-07-26	1996-11-18	Smithkline Beecham Corp	V/O mikroemulsioner
FR2709666B1 (fr)	1993-09-07	1995-10-13	Oreal	Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
DE4338046A1 (de)	1993-11-08	1995-05-11	Dietl Hans	Fettlösliche Arzneimittel erhaltende flüssige pharmazeutische Zubereitung zur oralen Anwendung
FR2730932B1 (fr)	1995-02-27	1997-04-04	Oreal	Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
SE9503143D0 (sv)	1995-09-12	1995-09-12	Astra Ab	New preparation

1995
- 1995-09-12 SE SE9503143A patent/SE9503143D0/xx unknown
1996
- 1996-09-04 BR BR9610089A patent/BR9610089A/pt not_active IP Right Cessation
- 1996-09-04 DK DK96931319T patent/DK0850046T3/da active
- 1996-09-04 ES ES96931319T patent/ES2186802T3/es not_active Expired - Lifetime
- 1996-09-04 PT PT96931319T patent/PT850046E/pt unknown
- 1996-09-04 WO PCT/SE1996/001097 patent/WO1997009964A1/en active IP Right Grant
- 1996-09-04 KR KR10-1998-0701818A patent/KR100448953B1/ko not_active IP Right Cessation
- 1996-09-04 AT AT96931319T patent/ATE228822T1/de active
- 1996-09-04 IL IL12363896A patent/IL123638A/en not_active IP Right Cessation
- 1996-09-04 JP JP51187897A patent/JP4203123B2/ja not_active Expired - Fee Related
- 1996-09-04 DE DE69625213T patent/DE69625213T2/de not_active Expired - Lifetime
- 1996-09-04 AU AU70037/96A patent/AU702366B2/en not_active Ceased
- 1996-09-04 CN CNB961981377A patent/CN1160057C/zh not_active Expired - Fee Related
- 1996-09-04 PL PL96325825A patent/PL325825A1/xx unknown
- 1996-09-04 SK SK283-98A patent/SK282390B6/sk unknown
- 1996-09-04 TR TR1998/00437T patent/TR199800437T1/xx unknown
- 1996-09-04 CA CA002230730A patent/CA2230730C/en not_active Expired - Fee Related
- 1996-09-04 HU HU9901215A patent/HUP9901215A3/hu unknown
- 1996-09-04 CZ CZ98643A patent/CZ64398A3/cs unknown
- 1996-09-04 US US08/718,485 patent/US6602511B2/en not_active Expired - Fee Related
- 1996-09-04 EP EP96931319A patent/EP0850046B1/en not_active Expired - Lifetime
- 1996-09-04 RU RU98106482/14A patent/RU2164134C2/ru active
- 1996-09-04 NZ NZ318530A patent/NZ318530A/en not_active IP Right Cessation
- 1996-09-04 EE EE9800070A patent/EE9800070A/xx unknown
1998
- 1998-02-25 IS IS4675A patent/IS4675A/is unknown
- 1998-03-05 MX MX9801755A patent/MX9801755A/es not_active IP Right Cessation
- 1998-03-09 NO NO19981021A patent/NO326404B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1997009964A1 (en)	1997-03-20
US6602511B2 (en)	2003-08-05
DE69625213D1 (de)	2003-01-16
IL123638A0 (en)	1998-10-30
DE69625213T2 (de)	2003-08-28
KR19990044569A (ko)	1999-06-25
JP4203123B2 (ja)	2008-12-24
EP0850046A2 (en)	1998-07-01
CZ64398A3 (cs)	1998-08-12
AU702366B2 (en)	1999-02-18
RU2164134C2 (ru)	2001-03-20
HUP9901215A2 (hu)	1999-08-30
CA2230730A1 (en)	1997-03-20
ES2186802T3 (es)	2003-05-16
EP0850046B1 (en)	2002-12-04
PL325825A1 (en)	1998-08-03
PT850046E (pt)	2003-03-31
HUP9901215A3 (en)	2000-06-28
IL123638A (en)	2004-06-20
CA2230730C (en)	2008-06-10
MX9801755A (es)	1998-08-30
DK0850046T3 (da)	2003-03-03
KR100448953B1 (ko)	2005-04-06
SK28398A3 (en)	1998-11-04
NO981021D0 (no)	1998-03-09
JPH11512424A (ja)	1999-10-26
CN1160057C (zh)	2004-08-04
ATE228822T1 (de)	2002-12-15
SK282390B6 (sk)	2002-01-07
AU7003796A (en)	1997-04-01
TR199800437T1 (xx)	1998-05-21
IS4675A (is)	1998-02-25
NO981021L (no)	1998-03-09
SE9503143D0 (sv)	1995-09-12
CN1201386A (zh)	1998-12-09
NZ318530A (en)	1999-09-29
US20010007663A1 (en)	2001-07-12
EE9800070A (et)	1998-10-15
BR9610089A (pt)	1999-01-05

Publication	Publication Date	Title
NO326404B1 (no)	2008-11-24	Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament
KR100410937B1 (ko)	2003-12-18	프로포폴을 함유하는 혈관주사용 마취제 조성물
KR100345627B1 (ko)	2003-03-15	단기간작용하는디히드로피리딘을함유하는약제학적유제및그의제조방법
CN100479856C (zh)	2009-04-22	用于亲水性化合物非肠道给药的缓释药物组合物
RU2028142C1 (ru)	1995-02-09	Фармацевтический раствор
EP0650721B1 (en)	2000-09-13	Cyclosporin soft capsule
KR101391020B1 (ko)	2014-04-30	수난용성 약제를 함유한 약학 조성물
WO2004041249A1 (en)	2004-05-21	Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same
DK175504B1 (da)	2004-11-15	Farmaceutisk præparat indeholdende 3alfa-hydroxy-5beta-pregnan-20-on og fremstilling deraf
EA033935B1 (ru)	2019-12-11	Инъекционный состав бупренорфина
AU574438B2 (en)	1988-07-07	Method for directed visceral metabolism of medium chain triglycerides
JP3132085B2 (ja)	2001-02-05	脂肪乳剤
JPH047722B2 (pt)	1992-02-12
RU2141313C1 (ru)	1999-11-20	Фармацевтическая эмульсия, содержащая биологически активные стероиды, и способ получения эмульсии
JP2632010B2 (ja)	1997-07-16	シクロスポリン製剤
TWI819756B (zh)	2023-10-21	包含塞納布啡的藥物組合物
JP2002540158A (ja)	2002-11-26	レトロウイルスプロテアーゼインヒビター用医薬エマルジョン
JPH0532549A (ja)	1993-02-09	脂肪乳剤
WO2002009670A1 (en)	2002-02-07	Liquid or semi-solid pharmaceutical excipient and pharmaceutical composition comprising the same

Legal Events

Date	Code	Title	Description
2011-05-09	MM1K	Lapsed by not paying the annual fees